GlassScriptPhysician profile
Michael Anthony Hall
NPI 1871657031
$6,899.06
in general payments reported to CMS, 2019-2025
33 companies · $455 in 2025
The $455 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,883 · 2020: $799 · 2021: $594 · 2022: $564 · 2023: $397 · 2024: $208 · 2025: $455.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,010 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $50.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,009.53 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $50.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $3,505.25 | 2019-2025 | Sublocade |
| Pfizer INC. | $547.04 | 2019-2025 | |
| Abbvie INC. | $395.94 | 2021-2024 | |
| Alkermes, INC. | $295.83 | 2019-2025 | Vivitrol |
| Allergan, INC. | $238.28 | 2019-2020 | |
| Integra Lifesciences Corporation | $226.33 | 2022-2024 | Integra, Surgimend, Omnigraft |
| Teva Pharmaceuticals USA, INC. | $210.64 | 2020-2022 | |
| Orexo US, INC. | $173.37 | 2019-2020 | |
| Braeburn INC. | $171.78 | 2023-2025 | Brixadi |
| Lilly USA, LLC | $152.82 | 2019-2023 | Jardiance |
| Ethicon US, LLC | $136.87 | 2021-2022 | |
| Axsome Therapeutics, INC. | $103.33 | 2025 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $94.22 | 2023-2024 | Rexulti |
| Shionogi INC | $91.33 | 2019 | |
| Conmed Corporation | $61.01 | 2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $59.92 | 2020-2021 | |
| Kaleo, INC. | $58.04 | 2019 | |
| Becton, Dickinson and Company | $50.00 | 2023 | Bd Safetyglide |
| Horizon Therapeutics Plc | $48.83 | 2020-2022 | |
| Antares Pharma, INC. | $30.00 | 2019-2020 | |
| Scilex Pharmaceuticals INC. | $29.76 | 2020-2021 | |
| Boston Scientific Corporation | $24.15 | 2025 | Obsidio |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $22.21 | 2025 | Relistor |
| Amgen INC. | $21.11 | 2021 | |
| Novo Nordisk INC | $20.15 | 2021 | |
| Amag Pharmaceuticals, INC. | $19.91 | 2019 | |
| Adlon Therapeutics L.P. | $19.27 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $18.29 | 2022 | |
| Tolmar, INC. | $16.30 | 2023 | |
| Gilead Sciences, INC. | $16.04 | 2020 | |
| Hikma Pharmaceuticals USA | $14.00 | 2022 | |
| La Jolla Pharmaceutical Company | $13.52 | 2021 | |
| Davol INC. | $13.52 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Hall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.